Corona Remedies IPO

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas. The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum. Competitive Strength: Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market. Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas. Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market. Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products. Qualified, experienced and entrepreneurial management team supported by marquee investors.

Information on this page is for general awareness only and is not investment advice. Grey market premium (when shown) is unofficial and indicative. Always read the RHP/DRHP and consult a qualified adviser before investing.